NUP210 (Nucleoporin 210), also known as gp210. is a transmembrane protein component of the nuclear pore complex (NPC), which regulates nucleocytoplasmic transport in eukaryotic cells. As one of the largest nucleoporins, NUP210 localizes to the inner nuclear membrane and plays a critical role in maintaining NPC structural integrity and nuclear envelope organization. It is involved in cellular processes such as cell differentiation, mitosis, and transcriptional regulation. Antibodies targeting NUP210 are valuable tools for studying its expression, localization, and function in both physiological and pathological contexts.
Research has linked NUP210 dysregulation to various diseases. In cancer, altered NUP210 expression is observed in malignancies like breast cancer and colorectal cancer, where it may influence tumor progression and metastasis. Antibodies against NUP210 enable detection of these expression changes via techniques like immunohistochemistry, Western blotting, or immunofluorescence. Additionally, NUP210 autoantibodies are identified in autoimmune conditions, such as primary biliary cholangitis (PBC), serving as diagnostic biomarkers.
Recent studies also explore NUP210's role in neurological disorders and muscle cell differentiation. Its antibody-based profiling contributes to understanding NPC-related mechanisms in disease pathogenesis, offering potential therapeutic insights. Commercial NUP210 antibodies are typically validated for specificity across human, mouse, and rat models, supporting diverse experimental applications.